Lombard Odier is proud to announce that it will sponsor the UK BioIndustry Association (BIA) 2019 CEO and Investor Forum on 24-25 June.

At Lombard Odier, we have always believed in rethinking the world around us, and in working with organisations that share our creative vision. We sponsor innovative projects at the forefront of technology and science, and those that share our responsible mind-set.

The BIA is a champion of the UK life sciences sector, supporting innovative companies which are creating transformative treatments for patients. The organisation works with government, investors and other organisations to support an ecosystem that enables life science companies to start and grow successfully and sustainably.

The UK is the third-largest life science cluster in the world. The sector – including the Golden Triangle of Oxford, Cambridge and London – is flourishing, despite the obvious uncertainties around Brexit. UK biotech firms are currently attracting record levels of funding¹; their number has soared by 65% in the last three years².

The dynamic UK life sciences sector shares many of Lombard Odier’s values – innovation, marrying profit with purpose, and embracing the power of digital technology to create new solutions.

The sector is helping address the issue of changing demographics, one of the long-term, structural trends we see transforming the global economy to a more sustainable model. UK research and drug development is tackling issues as diverse as ageing populations, cancer, chronic disease and antimicrobial resistance.

The BIA’s annual, two-day CEO and Investor Forum brings together leaders in the field, to debate the implications of a shifting international and domestic landscape, as well as to network, share experiences, best practice and the latest in thought leadership.

“The entrepreneurial spirit of the BIA’s members and investors, their dedication to improving lives, and their innovative use of technology to advance these aims are a good fit with our own philosophy,” said Lombard Odier Senior Private Banker Dylan Samuel, employee of LOESA UK.

To read more about our innovative partnerships, click here.
To read more about rethinking approaches to ecology and drug discovery, click here.

¹ Source: BIA
² Source, Downing LLP estimate, March 2019 (data from Q1 2016 – Q1 2019)